Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
Reynold A PanettieriCarlos Arturo CamargoTariq CheemaSherif G El BayadiStanley FielTania M VilaRenu G JainDawn MidwinterByron ThomashowAndrea Ludwig-SengpielDavid A LipsonPublished in: International journal of chronic obstructive pulmonary disease (2022)
FF/UMEC/VI reduced moderate/severe and severe exacerbation rates and improved lung function and health status versus BUD/FOR in patients with symptomatic COPD, regardless of recent exacerbation history.